The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
In a move that underscores growing confidence in early-stage biotech, ProQR Therapeutics announced positive Phase 1 data for its drug AX-0810 and concurrently raised $50 million in a share offering that included Eli Lilly. The deal signals large pharma's appetite for promising early-stage assets.
Sign in to access this content
Sign InEli Lilly's investment in ProQR comes as big pharmaceutical companies increasingly seek to diversify their pipelines through strategic partnerships. The capital injection provides ProQR with a solid runway to advance its candidate targeting an undisclosed chronic disease.
Eli Lilly (LLY) shares closed at $1,117.26 on June 24, 2026, trading between $1,100.98 and $1,135.14 during the session. Investors now await further clinical updates for AX-0810 and any regulatory milestones that could affect the stock's trajectory.